PepGen Announces Executive Team Promotions
PepGen, a clinical-stage biotechnology company, announced two executive promotions. Michelle Mellion, M.D., is now Chief Medical Officer, and Hayley Parker, Ph.D., is the new Senior Vice President of Global Regulatory Affairs. These promotions highlight their significant contributions to PepGen's clinical and regulatory strategies. Mellion has been pivotal in advancing the company's neuromuscular programs and has a rich background in clinical development and neurology. Parker has been essential in shaping PepGen's global regulatory strategy, bringing extensive experience in regulatory affairs and rare diseases. These leadership changes aim to bolster PepGen's efforts in developing innovative oligonucleotide therapies for severe neuromuscular and neurological diseases.
- Michelle Mellion's promotion to Chief Medical Officer is expected to enhance PepGen's clinical development capabilities.
- Hayley Parker's promotion to Senior Vice President of Global Regulatory Affairs strengthens the company's regulatory strategies.
- Both executives have extensive experience, which could positively impact PepGen's future clinical trials and commercialization efforts.
- The promotions underscore the company's commitment to advancing its oligonucleotide therapies pipeline.
- The press release does not provide any new clinical or financial data, leaving investors without concrete updates on the company's progress.
- There is no mention of timeline updates for clinical trial results, which may concern investors seeking short-term milestones.
Michelle Mellion, M.D., promoted to Chief Medical Officer
Hayley Parker, Ph.D., promoted to Senior Vice President, Global Regulatory Affairs
“I am excited to announce the well-deserved promotions of Michelle and Hayley, a true testament to their hard work, dedication, and leadership. Since joining PepGen, they have played integral roles in driving both our clinical and regulatory strategies, advancing our pipeline of differentiated oligonucleotides, and paving a path for future commercialization,” said James McArthur, Ph.D., President and CEO of PepGen. “As we continue to execute on our goals and prepare for preliminary data readouts and additional trial initiations, I look forward to working with our incredible team to take the vital next steps in bringing our potentially disease-modifying therapies to people living with rare muscle disorders."
Michelle Mellion, M.D., promoted to Chief Medical Officer, joined PepGen as Senior Vice President, Head of Clinical Development and has been instrumental in overseeing the Company’s global clinical development strategy, as well as advancing the Company’s neuromuscular programs into the clinic. She was also recently appointed to Medical Advisor of the FSHD Society. Previously, Dr. Mellion served in roles of increasing responsibility at Fulcrum Therapeutics, where she led the design and implementation of Phase I/II/III clinical trials for the company’s novel treatment of facioscapulohumeral muscular dystrophy. In parallel, she worked as an Attending Physician affiliated with Tufts Medical Center, specializing in Neurology as a member of their Pediatrics department. Earlier, Dr. Mellion held leadership roles at Vertex Pharmaceuticals and Biogen, as well as working as an Attending Neurologist in the Muscular Dystrophy Association (MDA) clinic and Attending Physician and Assistant Professor of Neurology at Alpert Medical School, Brown University. She completed her residency at Brown Medical School, received her M.D. from the Wake Forest University School of Medicine, and earned her B.A. in Molecular Biology from Colgate University.
Hayley Parker, Ph.D., promoted to Senior Vice President, Global Regulatory Affairs, joined PepGen as Vice President, Regulatory Affairs and has been pivotal in developing and executing the Company’s global regulatory strategy and in interacting with regulatory authorities. Previously, she served as Vice President, Regulatory Affairs at Scholar Rock, accountable for the global regulatory strategy for their lead neuromuscular program. Earlier, Dr. Parker gained experience in rare disease holding various leadership positions at Vertex Pharmaceuticals where, as part of the Regulatory Leadership team, she was Head of Global Labelling and global therapeutic strategic lead for early phase pain assets, and at Biogen working in rare diseases with high unmet medical need, such as Spinal Muscular Atrophy. She earned her Ph.D. in Molecular Biology and Respiratory Medicine at Imperial College,
About PepGen
PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611396164/en/
Investor Contact
Noel Donnelly
Chief Financial Officer
ndonnelly@pepgen.com
Media Contact
Julia Deutsch
Lyra Strategic Advisory
Jdeutsch@lyraadvisory.com
Source: PepGen Inc.
FAQ
What recent executive promotions did PepGen announce?
How might Michelle Mellion's promotion impact PepGen?
What role will Hayley Parker hold at PepGen?
What is PepGen's focus in biotechnology?
What are PepGen's Enhanced Delivery Oligonucleotide (EDO) peptides?
